Back to Search Start Over

Amlodipine added to quinapril vs quinapril alone for the treatment of hypertension in diabetes: the Amlodipine in Diabetes (ANDI) trial.

Authors :
Tobe S
Kawecka-Jaszcz K
Zannad F
Vetrovec G
Patni R
Shi H
Source :
Journal of clinical hypertension (Greenwich, Conn.) [J Clin Hypertens (Greenwich)] 2007 Feb; Vol. 9 (2), pp. 120-7.
Publication Year :
2007

Abstract

This randomized, comparative, parallel-group trial investigated strategies of blood pressure (BP)-lowering in patients with diabetes and hypertension. Patients not reaching goal BP (<130/80 mm Hg) after 4-week open-label treatment with quinapril 20 mg/d (n=374) received 40 mg/d quinapril (n=167) or 20 mg/d quinapril plus amlodipine besylate (5 mg/d; n=162) for 6 weeks. Patients receiving combination therapy vs monotherapy had significantly greater reductions in mean +/- SE sitting systolic BP (9.9+/-1.0 mm Hg vs 4.3+/-1.1 mm Hg; P<.001) and diastolic BP (6.5+/-0.6 mm Hg vs 2.7+/-0.6 mm Hg; P<.001). No significant differences between groups were observed in percentage of patients achieving goal BP (10.1% with combination therapy vs 8.2% with monotherapy). A clinically neutral effect was observed on high-sensitivity C-reactive protein in both groups. Treatments were well tolerated; fewer than 3% of patients in any group discontinued due to treatment-emergent or treatment-related adverse events. In diabetic hypertensive patients, 20 mg/d quinapril plus 5 mg/d amlodipine besylate was a more effective BP-lowering strategy than monotherapy with 40 mg/d quinapril.

Details

Language :
English
ISSN :
1524-6175
Volume :
9
Issue :
2
Database :
MEDLINE
Journal :
Journal of clinical hypertension (Greenwich, Conn.)
Publication Type :
Academic Journal
Accession number :
17272962
Full Text :
https://doi.org/10.1111/j.1524-6175.2007.06949.x